366 related articles for article (PubMed ID: 31233118)
1. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis.
Matsuura T; Maru Y; Izumiya M; Hoshi D; Kato S; Ochiai M; Hori M; Yamamoto S; Tatsuno K; Imai T; Aburatani H; Nakajima A; Hippo Y
Carcinogenesis; 2020 Jun; 41(4):490-501. PubMed ID: 31233118
[TBL] [Abstract][Full Text] [Related]
2. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
3. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
[TBL] [Abstract][Full Text] [Related]
4. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
5. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
6. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.
Zhang Z; Li H; Deng Y; Schuck K; Raulefs S; Maeritz N; Yu Y; Hechler T; Pahl A; Fernández-Sáiz V; Wan Y; Wang G; Engleitner T; Öllinger R; Rad R; Reichert M; Diakopoulos KN; Weber V; Li J; Shen S; Zou X; Kleeff J; Mihaljevic A; Michalski CW; Algül H; Friess H; Kong B
Gastroenterology; 2021 Nov; 161(5):1601-1614.e23. PubMed ID: 34303658
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
8. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
9. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
[TBL] [Abstract][Full Text] [Related]
10. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
11. Identification and manipulation of biliary metaplasia in pancreatic tumors.
Delgiorno KE; Hall JC; Takeuchi KK; Pan FC; Halbrook CJ; Washington MK; Olive KP; Spence JR; Sipos B; Wright CV; Wells JM; Crawford HC
Gastroenterology; 2014 Jan; 146(1):233-44.e5. PubMed ID: 23999170
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.
Bishehsari F; Zhang L; Barlass U; Preite NZ; Turturro S; Najor MS; Shetuni BB; Zayas JP; Mahdavinia M; Abukhdeir AM; Keshavarzian A
Int J Cancer; 2018 Oct; 143(8):1994-2007. PubMed ID: 29756386
[TBL] [Abstract][Full Text] [Related]
13. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
[TBL] [Abstract][Full Text] [Related]
14. ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.
Wang L; Yang H; Zamperone A; Diolaiti D; Palmbos PL; Abel EV; Purohit V; Dolgalev I; Rhim AD; Ljungman M; Hadju CH; Halbrook CJ; Bar-Sagi D; di Magliano MP; Crawford HC; Simeone DM
Genes Dev; 2019 Jun; 33(11-12):641-655. PubMed ID: 31048544
[TBL] [Abstract][Full Text] [Related]
15. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice.
Hoffman MT; Kemp SB; Salas-Escabillas DJ; Zhang Y; Steele NG; The S; Long D; Benitz S; Yan W; Margolskee RF; Bednar F; Pasca di Magliano M; Wen HJ; Crawford HC
Cell Mol Gastroenterol Hepatol; 2021; 11(2):349-369. PubMed ID: 32882403
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development.
Chu NJ; Anders RA; Fertig EJ; Cao M; Hopkins AC; Keenan BP; Popovic A; Armstrong TD; Jaffee EM; Zimmerman JW
Cancer Prev Res (Phila); 2020 Jul; 13(7):569-582. PubMed ID: 32409593
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
[TBL] [Abstract][Full Text] [Related]
18. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
Fukuda A
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
[TBL] [Abstract][Full Text] [Related]
20. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M
Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
